0.605
0.02 (2.54%)
| Penutupan Terdahulu | 0.590 |
| Buka | 0.596 |
| Jumlah Dagangan | 668,984 |
| Purata Dagangan (3B) | 8,073,593 |
| Modal Pasaran | 16,849,084 |
| Harga / Buku (P/B) | 8.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| EPS Cair (TTM) | -7.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 566.73% |
| Nisbah Semasa (MRQ) | 1.99 |
| Aliran Tunai Operasi (OCF TTM) | -27.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -18.79 M |
| Pulangan Atas Aset (ROA TTM) | -48.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -576.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | KALA BIO, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.13 |
|
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA’smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 1.91% |
| % Dimiliki oleh Institusi | 64.18% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Jan 2026 | Pengumuman | KALA BIO Settles Approximately $10.6 million of Debt |
| 05 Dec 2025 | Pengumuman | KALA BIO Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules |
| 04 Dec 2025 | Pengumuman | KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |